Fuad El-Hibri Sells 36,318 Shares of Emergent Biosolutions Inc (EBS) Stock

Emergent Biosolutions Inc (NYSE:EBS) Chairman Fuad El-Hibri sold 36,318 shares of Emergent Biosolutions stock in a transaction dated Tuesday, August 14th. The shares were sold at an average price of $55.98, for a total value of $2,033,081.64. The transaction was disclosed in a filing with the SEC, which is available at this hyperlink.

Fuad El-Hibri also recently made the following trade(s):

  • On Thursday, July 12th, Fuad El-Hibri sold 15,000 shares of Emergent Biosolutions stock. The shares were sold at an average price of $54.50, for a total value of $817,500.00.
  • On Monday, July 9th, Fuad El-Hibri sold 15,000 shares of Emergent Biosolutions stock. The shares were sold at an average price of $53.61, for a total value of $804,150.00.

Shares of Emergent Biosolutions stock opened at $59.03 on Friday. Emergent Biosolutions Inc has a 52-week low of $34.56 and a 52-week high of $60.00. The company has a market capitalization of $2.75 billion, a P/E ratio of 30.87, a PEG ratio of 1.18 and a beta of 1.20. The company has a current ratio of 5.59, a quick ratio of 4.15 and a debt-to-equity ratio of 0.01.

Emergent Biosolutions (NYSE:EBS) last announced its earnings results on Thursday, August 2nd. The biopharmaceutical company reported $1.07 earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of $0.88 by $0.19. Emergent Biosolutions had a return on equity of 15.09% and a net margin of 16.55%. The business had revenue of $220.20 million for the quarter, compared to analyst estimates of $208.94 million. During the same quarter last year, the firm earned $0.13 EPS. Emergent Biosolutions’s revenue for the quarter was up 118.5% compared to the same quarter last year. research analysts forecast that Emergent Biosolutions Inc will post 2.33 earnings per share for the current year.

A number of institutional investors have recently made changes to their positions in EBS. Summit Trail Advisors LLC raised its position in Emergent Biosolutions by 4,093.4% in the 1st quarter. Summit Trail Advisors LLC now owns 1,378,959 shares of the biopharmaceutical company’s stock valued at $1,379,000 after buying an additional 1,346,075 shares during the last quarter. BlackRock Inc. raised its position in Emergent Biosolutions by 20.2% in the 2nd quarter. BlackRock Inc. now owns 5,372,711 shares of the biopharmaceutical company’s stock valued at $271,268,000 after buying an additional 901,882 shares during the last quarter. Matarin Capital Management LLC acquired a new stake in Emergent Biosolutions in the 1st quarter valued at approximately $18,524,000. Prudential Financial Inc. raised its position in Emergent Biosolutions by 446.1% in the 1st quarter. Prudential Financial Inc. now owns 416,921 shares of the biopharmaceutical company’s stock valued at $21,951,000 after buying an additional 340,578 shares during the last quarter. Finally, Millennium Management LLC raised its position in Emergent Biosolutions by 29.6% in the 1st quarter. Millennium Management LLC now owns 917,065 shares of the biopharmaceutical company’s stock valued at $48,283,000 after buying an additional 209,581 shares during the last quarter. 82.72% of the stock is currently owned by institutional investors and hedge funds.

EBS has been the topic of several recent analyst reports. Zacks Investment Research cut Emergent Biosolutions from a “buy” rating to a “hold” rating in a report on Tuesday, May 1st. Chardan Capital lifted their price objective on Emergent Biosolutions from $53.00 to $57.00 and gave the company a “buy” rating in a report on Friday, August 3rd. Wells Fargo & Co reiterated a “market perform” rating on shares of Emergent Biosolutions in a report on Wednesday, April 25th. Cantor Fitzgerald initiated coverage on Emergent Biosolutions in a report on Monday, June 11th. They set a “buy” rating and a $62.00 price objective on the stock. Finally, Argus initiated coverage on Emergent Biosolutions in a report on Wednesday, June 13th. They set a “buy” rating and a $62.00 price objective on the stock. Two analysts have rated the stock with a hold rating and seven have given a buy rating to the company’s stock. Emergent Biosolutions currently has an average rating of “Buy” and a consensus price target of $59.57.

Emergent Biosolutions Company Profile

Emergent BioSolutions Inc focuses on the development, manufacture, and commercialization of medical countermeasures that address public health threats. Its products address public health threats primarily chemical, biological, radiological, nuclear, and explosive-related threats, as well as infectious diseases.

Read More: Growth Stocks, What They Are, What They Are Not

Insider Buying and Selling by Quarter for Emergent Biosolutions (NYSE:EBS)

Receive News & Ratings for Emergent Biosolutions Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Emergent Biosolutions and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply